A large study that took place over nearly nine years has concluded that men receiving testosterone replacement therapy have a lower risk of cancer than those not receiving, or balancing, their hormones.  The study confirmed that there is no increased risk of cancer while on TRT, including prostate cancer.

This is something that many testosterone doctors have known for years but the myth has continued to propagate nonetheless.

“Men have been so concerned about the relationship between testosterone and prostate cancer development so it’s refreshing, finally, to have a solid clinical answer that there is no relationship between the two,” said Charles Blaisdell, Clinic Director at Boston Testosterone Partners, a center specializing in the treatment of Low Testosterone in men.

The study that was conducted took place that the Baylor College of Medicine in Houston by Dr. Michael L. Eisenberg and his associates.  It began by evaluating their database of men who had a baseline serum testosterone level.  Of those men, they then documented those who were on testosterone replacement therapy.  The study’s participants included 750 men who resided in Texas.  The study went on to link the records of these men to the Texas Cancer Registry to confirm or deny the incidence of cancer in all 750.

Out of the 750 men chosen for the study 333 of them were on testosterone replacement therapy and 417 of them were not.  The average age of the male participants was 47 years and the mean time frame that they were studied was 8.7 years.

“The study is important for aging men with untreated low testosterone,” says Blaisdell.  “Of the 750 men in the study a total of 55 of the men had developed some form of cancer in the almost 9 years.  But, importantly, of the 55, only 22 of the men were on those on testosterone replacement therapy while the other 33 were the men who were not receiving the benefits of testosterone replacement therapy,” he went on.

“These researchers even went as far as to adjust the age and years of therapy; they still found no difference in the risk of developing cancer of the men undergoing testosterone replacement therapy,” Blaisdell said.

When compared to the general Texas population, men on testosterone replacement therapy had an age-adjusted standardized cancer incident rate of 1.5 while those who were not on testosterone replacement therapy had a standardized cancer incident rate of 1.7.

The men who were not undergoing testosterone therapy had a much higher rate of cancer.  Blaisdell postulates, “This is simply because men who treat their hormone deficiencies have multi levels of health protections.  First, they are perfectly optimizing their testosterone and hormone levels so their hormonal health is second to none.  Next, men who undertake TRT, generally will care for themselves in all other aspects of health.  Regular physical exercise, mental exercise such as yoga or meditation and clean diets are commonplace among all our patients.  Men with perfectly optimized hormones do not sit on the couch with a beer and a bag of chips in each hand”

These researchers also undertook to analyze the incidents of prostate cancer.  As to that risk, the researchers discovered that men on testosterone replacement had an age adjusted standardized cancer incident rate of 2.6 versus a higher standardized cancer incident rate of 3.7 of men who were not on testosterone replacement therapy.

“We had hoped for these results,” Dr. Eisenberg said during a session at the annual meeting of the American Urological Association. “Certainly people are worried about testosterone in terms of prostate cancer development.”

This is not the first study to conclude that Testosterone Replacement Therapy has been reducing the risk in prostate cancer in men.  In a study reported this year also, Stanford researchers compared data of 722 men as well as the general population and concluded there was a decrease in prostate cancer incidence among those treating themselves with medical testosterone therapy.  (The Journal of Urology, Volume 189, Issue 4, Supplement , Pages e617-e618, April 2013.)

Testosterone therapy also plays a big role in lengthening the life span of men.

“Today, we recognize, based on dozens of studies, its importance relative to health issues such as diabetes, obesity, metabolic syndrome, and osteoporosis,” says Boston Testosterone Doctor, Abraham Morgentaler.  “Men with low T die sooner than men with normal levels of testosterone,” says Morgentaler, Harvard Doctor and author of the leading men’s health book Testosterone for Life: Recharge Your Vitality, Sex Drive, Muscle Mass, and Overall Health.

Boston Testosterone Partners is uniquely positioned to conduct testing for Low Testosterone for men nationwide.  If you are interested in having yourself checked for Low T you may contact Charles Blaisdell at CBlaisdell@CoreNewEngland.com

Boston Testosterone Partners is a Testosterone Replacement, Wellness and Preventative Medicine Medical Center that treats and prevents the signs and symptoms associated with Andropause and hormone imbalances.  With affiliates nationally, BTP offers hormone replacement therapy, weight loss protocols, erectile dysfunction (ED), Sermorelin-GHRP2 therapy and neutraceutical injectable therapies for men and women.  Their medical facilities offer physician examinations and treatment programs that incorporate the latest in medical science.   For more information, reviews and testimonials go to their Facebook Wall or call 855-617-MEDS (6337)

Advertisements